Investigational drug · Phase 2
Nelmastobart
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Nelmastobart"
First trial start
2025
Jun 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nelmastobart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer (CRC)
- Recurrent Colorectal Cancer
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nelmastobart" as an intervention, largest first.
STCube, Inc.Industry
NCT07306624 · 62 participants (planned) · Start Jan 10, 2026 · Primary completion Aug 31, 2027
Drug: Nelmastobart and Docetaxel · For: Non Small Cell Lung Cancer
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 5 sites in all
- Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal CancerActive, not recruiting
Korea University Anam HospitalAcademic, hospital or other
NCT05990543 · 59 participants (planned) · Start Jan 29, 2024 · Primary completion Dec 1, 2025
Drug: Nelmastobart and Capecitabine · For: Recurrent or Metastatic Colorectal Cancer
Sites: Seoul, South Korea
STCube, Inc.Industry
NCT06873763 · 52 participants (planned) · Start Jun 9, 2025 · Primary completion Dec 2025
Drug: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab · For: Metastatic Colorectal Cancer (CRC); Recurrent Colorectal Cancer
Sites: Seongnam-si, South Korea; Seoul, South Korea · 5 sites in all
- Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal CancerNot yet recruiting
STCube, Inc.Industry
NCT07656038 · 45 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 31, 2028
Drug: Nelmastobart in combination with TAS-102 and Bevacizumab · For: Colonrectal Cancer (CRC)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Colorectal Cancer (CRC)
- RilogrotugPhase 31 trial
AVEO Pharmaceuticals, Inc. · Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome
- SSGJ-706Phase 23 trials
Shenyang Sunshine Pharmaceutical Co., LTD. · Non Small Cell Lung Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
- DES-1357Phase 21 trial
D. E. Shaw Research, LLC · Metastatic Colorectal Cancer (CRC)
- ETX-929Phase 21 trial
Ensem Therapeutics · Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer
- HSK42360-NaPhase 21 trial
Haisco Pharmaceutical Group Co., Ltd. · Metastatic Colorectal Cancer (CRC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.